ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) — insider trading
Health Care · NASDAQ
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) has 11 reported SEC Form 4 insider transactions in our data (latest 2026-06-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | Marantz Jing L. | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Marquet Magda | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Slaoui Moncef | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Markels John | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | BARLOW JAMES F | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | FARRELL PETER C | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | HOLMES EDWARD W | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-05-01 | MULROY DENNIS | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 100,000 | $0.00 | $0 | Form 4 |
| 2025-12-17 | Payne Joseph E | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 175,000 | $0.00 | $0 | Form 4 |
| 2025-12-17 | Chivukula Pad | Officer (Chief Scientific Officer & COO) | Grant / award / vesting (derivative) | 54,000 | $0.00 | $0 | Form 4 |
| 2025-12-17 | Roberts Joseph | Officer (Controller) | Grant / award / vesting (derivative) | 10,000 | $0.00 | $0 | Form 4 |
Ask the chat about ARCT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT).
Last updated 2026-06-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.